Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiaokui Mo

Showing results (121-130 of 207) with videos related to

Pageof 21
Sort By:
Journal of Extracellular Vesicles|July 19, 2017
Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cellsXiaohua Zhu, Mohamed Badawi, Steven Pomeroy, et al.
Mabs|March 6, 2014
Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemiaCarolyn M Cheney, Deborah M Stephens, Xiaokui Mo, et al.
Radiology|May 5, 2017
MR Elastography-derived Stiffness: A Biomarker for Intervertebral Disc DegenerationBenjamin A Walter, Prasath Mageswaran, Xiaokui Mo, et al.
The Journal of Biological Chemistry|December 3, 2015
Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) FunctionLi Ren, Amanda Campbell, Huiqing Fang, et al.
Stem Cells (Dayton, Ohio)|February 14, 2013
MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cellsKaushal Joshi, Yeshavanth Banasavadi-Siddegowda, Xiaokui Mo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2012
Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignanciesYicheng Mao, Georgia Triantafillou, Erin Hertlein, et al.
Oncotarget|March 9, 2018
Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemiaBhavani Gopalakrishnan, Carolyn Cheney, Rajeswaran Mani, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 22, 2022
Disruption of Nurse-like Cell Differentiation as a Therapeutic Strategy for Chronic Lymphocytic LeukemiaGiovanna Merchand-Reyes, Ramasamy Santhanam, Frank H Robledo-Avila, et al.
Oncoimmunology|October 21, 2016
Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activatorPrashant Trikha, Robert L Plews, Andrew Stiff, et al.
Metabolites|July 25, 2019
Metabolic Regulation of Glycolysis and AMP Activated Protein Kinase Pathways during Black Raspberry-Mediated Oral Cancer ChemopreventionThomas J Knobloch, Nathan M Ryan, Lei Bruschweiler-Li, et al.
Pageof 21

Showing results (121-130 of 207) with videos related to

Sort By:
Pageof 21
Journal of Extracellular Vesicles|July 19, 2017
Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cellsXiaohua Zhu, Mohamed Badawi, Steven Pomeroy, et al.
Mabs|March 6, 2014
Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemiaCarolyn M Cheney, Deborah M Stephens, Xiaokui Mo, et al.
Radiology|May 5, 2017
MR Elastography-derived Stiffness: A Biomarker for Intervertebral Disc DegenerationBenjamin A Walter, Prasath Mageswaran, Xiaokui Mo, et al.
The Journal of Biological Chemistry|December 3, 2015
Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) FunctionLi Ren, Amanda Campbell, Huiqing Fang, et al.
Stem Cells (Dayton, Ohio)|February 14, 2013
MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cellsKaushal Joshi, Yeshavanth Banasavadi-Siddegowda, Xiaokui Mo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2012
Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignanciesYicheng Mao, Georgia Triantafillou, Erin Hertlein, et al.
Oncotarget|March 9, 2018
Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemiaBhavani Gopalakrishnan, Carolyn Cheney, Rajeswaran Mani, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 22, 2022
Disruption of Nurse-like Cell Differentiation as a Therapeutic Strategy for Chronic Lymphocytic LeukemiaGiovanna Merchand-Reyes, Ramasamy Santhanam, Frank H Robledo-Avila, et al.
Oncoimmunology|October 21, 2016
Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activatorPrashant Trikha, Robert L Plews, Andrew Stiff, et al.
Metabolites|July 25, 2019
Metabolic Regulation of Glycolysis and AMP Activated Protein Kinase Pathways during Black Raspberry-Mediated Oral Cancer ChemopreventionThomas J Knobloch, Nathan M Ryan, Lei Bruschweiler-Li, et al.
Pageof 21